Pooled analysis of rofecoxib placebo-controlled clinical trial data lessons for postmarket pharmaceutical safety surveillance

Archives of Internal Medicine

Volumn 169, Issue 21, 2009, Pages 1976-1984

  Ross, Joseph S ^a   Madigan, David ^b   Hill, Kevin P ^c   Egilman, David S ^d   Wang, Yongfei ^e   Krumholz, Harlan M ^e  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c MCLEAN HOSPITAL   (United States)

^d BROWN UNIVERSITY   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ROFECOXIB;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; INCIDENCE; MORTALITY; OUTCOME ASSESSMENT; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIORITY JOURNAL; THROMBOEMBOLISM;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CARDIOVASCULAR SYSTEM; CYCLOOXYGENASE 2 INHIBITORS; DRUG INDUSTRY; HUMANS; INCIDENCE; LACTONES; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SAFETY-BASED DRUG WITHDRAWALS; SULFONES; TIME FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 73249133520     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2009.394     Document Type: Article

References (44)

1. Scolnick EM. E-mail communication to Deborah Shapiro, Alise Reicin, and Alan Nies re: vigor [Bates No. MRK-ABH0016219, Cona v. Merck & Co Inc], March 9 2000. http://dida.library.ucsf.edu/pdf/oxx00c10. Accessed December 1, 2008.
2. Food and Drug Administration. Medical officer review: Vioxx (rofecoxib) NDA 21-042 (capsules) and 21-052 (oral solution). http://www.fda.gov/cder/foi/ nda/99/021042-52-Vioxx.htm. Accessed December 1, 2008.
3. Bresalier RS, Sandler RS, Quan H, et al; Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352(11):1092-1102.
4. Gilmartin RV. Summary of prepared testimony, Raymond V. Gilmartin, president, chairman and chief executive officer, Merck and Co., Inc before the United States Senate Committee on Finance, November 18, 2004. http://finance.senate.gov/hearings/testimony/2004test/111804RGtest.pdf. Accessed June 25, 2009.
5. Antman EM, DeMets D, Loscalzo J. Cyclooxygenase inhibition and cardiovascular risk. Circulation. 2005;112(5):759-770.
6. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med. 2004;351(17):1709-1711.
7. Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004;364(9450):2021-2029.
8. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA; American Heart Association. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115(12):1634-1642.
9. Konstam MA, Weir MR, Reicin A, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation. 2001;104(19):2280-2288.
10. Reicin AS, Shapiro D, Sperling RS, Barr E, Yu Q. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). Am J Cardiol. 2002;89(2):204-209.
11. Weir MR, Sperling RS, Reicin A, Gertz BJ. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. Am Heart J. 2003;146(4):591-604.
12. Kerr DJ, Dunn JA, Langman MJ, et al; VICTOR Trial Group. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N Engl J Med. 2007;357(4):360-369.
13. van Adelsberg J, Gann P, Ko AT, et al. The VIOXX in Prostate Cancer Prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups. Curr Med Res Opin. 2007;23(9):2063-2070.
14. Ehrich EW, Schnitzer TJ, McIlwain H, et al; Rofecoxib Osteoarthritis Pilot Study Group. Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. J Rheumatol. 1999;26(11):2438-2447.
15. Ehrich EW, Bolognese JA, Watson DJ, Kong SX. Effect of rofecoxib therapy on measures of health-related quality of life in patients with osteoarthritis. Am J Manag Care. 2001;7(6):609-616.
16. Saag K, van der Heijde D, Fisher C, et al; Osteoarthritis Studies Group. Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Arch Fam Med. 2000;9(10):1124-1134.
17. Day R, Morrison B, Luza A, et al; Rofecoxib/Ibuprofen Comparator Study Group. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Arch Intern Med. 2000;160(12):1781-1787.
18. Laine L, Harper S, Simon T, et al; Rofecoxib Osteoarthritis Endoscopy Study Group. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology. 1999;117(4):776-783.
19. Hawkey C, Laine L, Simon T, et al; The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2000;43(2):370-377.
20. Truitt KE, Sperling RS, Ettinger WH Jr, et al; Phase III Rofecoxib Geriatric Study Group. A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis. Aging (Milano). 2001;13(2):112-121.
21. Kivitz AJ, Greenwald MW, Cohen SB, et al; Protocol 085 Study Investigators. Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: a randomized controlled trial. J Am Geriatr Soc. 2004;52(5):666-674.
22. Weaver AL, Messner RP, Storms WW, et al. Treatment of patients with osteoarthritis with rofecoxib compared with nabumetone. J Clin Rheumatol. 2006; 12(1):17-25.
23. Smugar SS, Schnitzer TJ, Weaver AL, Rubin BR, Polis AB, Tershakovec AM. Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies. Curr Med Res Opin. 2006;22(7):1353-1367.
24. Laine L, Maller ES, Yu C, Quan H, Simon T. Ulcer formation with low-dose entericcoated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology. 2004;127(2):395-402.
25. Birbara C, Ruoff G, Sheldon E, et al. Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies. Curr Med Res Opin. 2006;22(1):199-210.
26. Schnitzer TJ, Truitt K, Fleischmann R, et al; Phase II Rofecoxib Rheumatoid Arthritis Study Group. The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Clin Ther. 1999;21(10):1688-1702.
27. Truitt KE, Lee M, DeTora LM, Anderson M, Zhao PL. Results of a pivotal (phase III) placebo and active comparator controlled efficacy trial of rofecoxib 12.5 and 25 mg in adult patients with rheumatoid arthritis (RA). Arthritis Rheum. 2001;44:S369.
28. Geusens PP, Truitt K, Sfikakis P, et al. A placebo and active comparatorcontrolled trial of rofecoxib for the treatment of rheumatoid arthritis. Scand J Rheumatol. 2002;31(4):230-238.
29. Hawkey CJ, Laine L, Simon T, Quan H, Shingo S, Evans J; Rofecoxib Rheumatoid Arthritis Endoscopy Study Group. Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study. Gut. 2003;52(6):820-826.
30. Thal LJ, Ferris SH, Kirby L, et al; Rofecoxib Protocol 078 study group. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology. 2005;30(6):1204-1215.
31. Reines SA, Block GA, Morris JC, et al; Rofecoxib Protocol 091 Study Group. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology. 2004;62(1):66-71.
32. Nickel JC, Pontari M, Moon T, et al; Rofecoxib Prostatitis Investigator Team. A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. J Urol. 2003;169(4):1401-1405.
33. Katz N, Ju WD, Krupa DA, et al; Vioxx Chronic Low Back Pain Study Group. Efficacy and safety of rofecoxib in patients with chronic low back pain: results from two 4-week, randomized, placebo-controlled, parallel-group, double-blind trials. Spine (Phila Pa 1976). 2003;28(9):851-859.
34. Baron JA, Sandler RS, Bresalier RS, et al. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet. 2008;372(9651):1756-1764.
35. Friedman LM, Furberg CD, Demets DL. Fundamentals of Clinical Trials. 3rd ed. New York, NY: Springer Publishing Co; 1999.
36. Martin JSJ. Martin report: report of The Honorable John S. Martin, Jr. to the special committee of the board of directors of Merck & Co., Inc. concerning the conduct of senior management in the development and marketing of Vioxx, September 5, 2006. http://www.merck.com/newsroom/vioxx/martin-report. html. Accessed October 22, 2008.
37. Institute of Medicine. The Future of Drug Safety: Promoting and Protecting the Health of the Public. Washington, DC: National Academy Press; 2006.
38. Bombardier C, Laine L, Reicin A, et al; VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343(21):1520-1528, 2, 1528.
39. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Antiplatelet Trialists' Collaboration. Br Med J (Clin Res Ed). 1988;296(6618):320-331.
40. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ. 1994;308(6921):81-106.
41. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71-86.
42. Gardner MJ, Altman DG. Confidence intervals rather than P values: estimation rather than hypothesis testing. Br Med J (Clin Res Ed). 1986;292(6522):746-750.
43. Liu JP. Rethinking statistical approaches to evaluating drug safety. Yonsei Med J. 2007;48(6):895-900.
44. Curfman GD, Morrissey S, Drazen JM. Expression of concern: Bombardier et al "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8. N Engl J Med. 2005;353(26):2813-2814.